Rankings
▼
Calendar
TGTX Q3 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q3 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+5242.1% YoY
Gross Profit
$2M
85.6% margin
Operating Income
-$85M
-4193.5% margin
Net Income
-$86M
-4218.6% margin
EPS (Diluted)
$-0.65
QoQ Revenue Growth
+31.4%
Cash Flow
Operating Cash Flow
-$67M
Free Cash Flow
-$67M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$410M
Total Liabilities
$98M
Stockholders' Equity
$312M
Cash & Equivalents
$327M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$38,000
+5242.1%
Gross Profit
$2M
$38,000
+4473.7%
Operating Income
-$85M
-$86M
+0.7%
Net Income
-$86M
-$87M
+1.8%
Revenue Segments
Product revenue, net
$2M
98%
License revenue
$38,000
2%
← FY 2021
All Quarters
Q4 2021 →